Literature DB >> 34275974

Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021.

Cui Xiaoni1, Wang Pengxiang1, Wei Zhun2.   

Abstract

In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19), and the resulting pandemic has caused widespread health problems and social and economic disruption. Thus far in 2021, more than 4 million people worldwide have died from COVID-19, so safe and efficacious vaccines are urgently needed to restore normal economic and social activities. According to the official guidance documents of the World Health Organization (WHO), vaccines based on four major strategies including mRNA, adenoviral vectors, inactivated viruses, and recombinant proteins have entered the stage of emergency use authorization and pre-certification evaluation. The current review summarizes these vaccines and it looks ahead to the development of additional COVID-19 vaccines in the future.

Entities:  

Keywords:  COVID-19; adenoviral vectors; inactivated viruses; mRNA; recombinant proteins; vaccine research

Year:  2021        PMID: 34275974     DOI: 10.5582/ddt.2021.01064

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  3 in total

Review 1.  Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies.

Authors:  Shuen-Iu Hung; Ivan Arni C Preclaro; Wen-Hung Chung; Chuang-Wei Wang
Journal:  Biomedicines       Date:  2022-05-28

2.  COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.

Authors:  Zhujun Cao; Chenxi Zhang; Shuang Zhao; Zike Sheng; Xiaogang Xiang; Ruokun Li; Zhuping Qian; Yinling Wang; Bin Chen; Ziqiang Li; Yuhan Liu; Baoyan An; Huijuan Zhou; Wei Cai; Hui Wang; Honglian Gui; Haiguang Xin; Qing Xie
Journal:  Infect Dis Poverty       Date:  2022-05-16       Impact factor: 10.485

3.  The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.

Authors:  Eman Farid; Juber Herrera-Uribe; Nigel J Stevenson
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.